Jae-Ho Shin

Dr. Jae-Ho Shin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJaeok Lee
Jaeok Lee
JKJiyeon Kang
Jiyeon Kang
NKNa-Yun Kwon
Na-Yun Kwon
ASAneesh Sivaraman
Aneesh Sivaraman
RNRavi Naik
Ravi Naik
HLHwa Jeong Lee
Hwa Jeong Lee
P-glycoprotein (P-gp) inhibition has been studied to overcome multidrug resistance in cancer chemotherapy but failed in clinical trials due to low/toxic effects. Recently, a dual modulation of transporters and natural derivatives have been examined to surmount this limitation. We examined breast cancer resistance protein (BCRP) inhibition in vitro and in vivo by P-gp inhibitors derived from natural compounds in previous studies. P-gp inhibitors increased the accumulation of the anticancer drug, topotecan (TPT)—a substrate of P-gp and BCRP, albeit with higher affinity for BCRP—in BCRP-overexpressing cells, resulting in cell death. These dual inhibitors, when orally co-administered with TPT, enhanced TPT bioavailability with slightly reduced total oral clearance (Clt/F) in rats. In xenograft mice, they strengthened oral TPT-induced tumor reduction with no alterations in body weight. Moreover, we investigated the effects of an oral drug formulation (Cremophor® EL, Tween® 80, and polyethylene glycol 400) on the transporters function. The excipients increased TPT accumulation in P-gp- or BCRP-overexpressing cells. Oral TPT bioavailability was higher with the formulation than with a control, as shown by the increases in the maximum plasma concentration (Cmax) and the area under the plasma concentration–time curve from zero to infinity (AUCINF) (p< 0.01). Therefore, oral TPT bioavailability was enhanced by P-gp/BCRP dual inhibition, which resulted in a formulation-mediated increase in absorption and decrease in elimination, and a dual inhibitor-mediated decrease in elimination. These results suggest that the combination of dual inhibition by a natural derivative and the drug formulation can be a useful clinical approach.

11 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SHSoo-Yeon Hwang
Soo-Yeon Hwang
SCSeul-Ki Choi
Seul-Ki Choi
SSSeung Hee Seo
Seung Hee Seo
HJHyunji Jo
Hyunji Jo
JSJae-Ho Shin
Jae-Ho Shin
YKYoungjoo Kwon
Youngjoo Kwon
Trastuzumab (TZMB) is widely used as first line therapy for breast cancer (BC) patients overexpressing human epidermal growth factor receptor 2 (HER2). Despite its clinical benefits, many patients suffer from primary or secondary resistance to this drug within one year. As diverse molecular mechanisms occur contemporaneously during the resistance development, we focused on elucidating the role of heat shock protein 27 (HSP27) in TZMB-resistance, as this protein simultaneously regulates the function of diverse client molecules that are involved in the resistance mechanism. By extensively utilizing TZMB-refractory breast cancer cell lines transduced with diverse phosphovariants of HSP27, our study newly revealed that specific phosphorylation of HSP27 at S15 promoted its S78 phosphorylation and served as key mediator to promote direct interactions that increase the stability of HER2 and protein kinase B (AKT). This phosphorylation promoted nuclear translocation of HER2, enhancing the distinct nuclear function of HER2 that promoted AKT activation and cyclin D1 expression. Co-administration of TZMB and a functional inhibitor of HSP27, J2, significantly reduced the S15/78 phosphorylation of HSP27, which downregulated HER2 and its downstream signals, sensitizing TZMB-refractory cell, and JIMT1-xenograft mouse models to TZMB. Collectively, p-HSP27S15 could serve as a valuable predictive marker and also a therapeutic target for TZMB-resistance.

28 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HYHawon Yoo
Hawon Yoo
SCSeul-Ki Choi
Seul-Ki Choi
JLJaeok Lee
Jaeok Lee
PSPARK SOHYEON
PARK SOHYEON
YPYou Na Park
You Na Park
YLYun-Sil Lee
Yun-Sil Lee
Relationships between heat shock protein 27 (HSP27) and cancer aggressiveness, metastasis, drug resistance, and poor patient outcomes in various cancer types including non-small cell lung cancer (NSCLC) were reported, and inhibition of HSP27 expression is suggested to be a possible strategy for cancer therapy. Unlike HSP90 or HSP70, HSP27 does not have an ATP-binding pocket, and no effective HSP27 inhibitors have been identified. Previously, NSCLC cancer cells were sensitized to radiation and chemotherapy when co-treated with small molecule HSP27 functional inhibitors such as zerumbone (ZER), SW15, and J2 that can induce abnormal cross-linked HSP27 dimer. In this study, cancer inhibition effects of NA49, a chromenone compound with better solubility, longer circulation time, and less toxicity than J2, were examined in combination with anticancer drugs such as cisplatin and gefitinib in NSCLC cell lines. When the cytotoxic drug cisplatin was treated in combination with NA49 in epidermal growth factor receptors (EGFRs) WT cell lines, sensitization was induced in an HSP27 expression-dependent manner. With gefitinib treatment, NA49 showed increased combination effects in both EGFR WT and Mut cell lines, also with HSP27 expression-dependent patterns. Moreover, NA49 induced sensitization in EGFR Mut cells with a secondary mutation of T790M when combined with gefitinib. Augmented tumor growth inhibition was shown with the combination of cisplatin or gefitinib and NA49 in nude mouse xenograft models. These results suggest the combination of HSP27 inhibitor NA49 and anticancer agents as a candidate for overcoming HSP27-mediated drug resistance in NSCLC patients.

21 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JLJueun Lee
Jueun Lee
SKSeojeong Kim
Seojeong Kim
YJYeajin Ju
Yeajin Ju
MSMinjung Seo
Minjung Seo
HKHyeri Kim
Hyeri Kim
GHGeum-Sook Hwang
Geum-Sook Hwang
Metabolic dysfunction-associated steatohepatitis (MASH) is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD) that is characterized by hepatic steatosis, inflammation, and fibrosis and can progress to cirrhosis and hepatocellular carcinoma. AMP-activated protein kinase (AMPK) is a critical regulator of cellular energy homeostasis and has emerged as a promising therapeutic target for MASH. This study aimed to evaluate the mechanism of action of KN21, a novel direct AMPK activator, in a diet-induced MASH mouse model to support its therapeutic potential. C57BL6J mice were fed a choline-deficient, L-amino acid-defined high-fat diet (CDAHFD) to induce MASH, followed by treatment with KN21. Metabolomic and lipidomic profiling were performed using liquid chromatography-mass spectrometry. Histological, biochemical, and molecular analyses were conducted to assess hepatic steatosis and fibrosis. KN21 treatment significantly promoted hepatic AMPK phosphorylation, reduced the liver-to-body weight ratio, mitigated hepatic steatosis, and decreased fibrosis in CDAHFD-fed mice. Lipidomic analysis revealed that KN21 reduced long-chain triacylglycerol (TAG) accumulation, whereas metabolomic analysis revealed that the abundance of pyrimidine metabolites, especially uridine and uracil, was restored in CDAHFD-fed mice. These changes were strongly correlated with reduced fibrotic marker levels, suggesting that KN21 attenuates both lipid accumulation and fibrosis, which are associated with TAG and pyrimidine metabolism and homeostasis. KN21 effectively reduced hepatic steatosis and fibrosis in a diet-induced MASH mouse model through AMPK activation, accompanied by modulation and restoration of long-chain TAG and pyrimidine metabolism. These findings highlight its potential as a promising therapeutic strategy for MASH and provide new insights into the metabolic mechanisms underlying AMPK-mediated hepatoprotection.

Verified
Journal Article
Open access
PDF file
SMSun Ho Min
Sun Ho Min
JSJae-Ho Shin
Jae-Ho Shin
SPSunjoo Park
Sunjoo Park
RCRonglan Cui
Ronglan Cui
YHYoun Ji Hur
Youn Ji Hur
JCJaeho Cho
Jaeho Cho
Radiation-induced lung inflammation (RILI) is a major complication of thoracic radiotherapy, characterized by excessive inflammation and subsequent fibrosis that compromise pulmonary function and treatment outcomes. This study explores the pharmacological properties of a newly synthesized Lipoxin A4 analogue (CYNC-2) to mitigate RILI by modulating the AMP-activated protein kinase (AMPK)/NOD-like receptor family pyrin domain containing 3(NLRP3) inflammasome pathway. A murine RILI model was established in mice by delivering a single high-dose (ablative) X-ray irradiation to the left lung. Mice in the treatment group received CYNC-2 via tail-vein injection three times per week for 2 weeks. The effects of CYNC-2 on RILI were evaluated histological, immunohistochemical analysis of lung tissues, cytokine profiling, lung function testing using a FlexiVent system, and micro-computed tomography (micro-CT) imaging of lung damage. In parallel, two human lung cell lines—L132 (normal bronchial epithelial cells) and A549 (lung carcinoma cells)—were irradiated with 6 Gy X-rays and treated with CYNC-2 to assess cell viability and changes in AMPK/NLRP3 pathway markers via qPCR and immunofluorescence. Lung tissue sample from patients who underwent thoracic radiotherapy were also examined to validate key findings. CYNC-2 activated AMPK and inhibited mTOR signaling, which suppressed NLRP3 inflammasome activation and led to reduced secretion of pro-inflammatory cytokines (IL-1β, IL-6, and TGF-β1). In vitro, CYNC-2 mitigated radiation-induced inflammatory responses and preserved cellular viability. Overall, CYNC-2 effectively dampened acute pulmonary in the RILI model. These findings suggest that targeting the AMPK/NLRP3 inflammasome pathway via a stable LXA4 analogue such as CYNC-2 is a promising therapeutic strategy to improve clinical outcomes for patients receiving thoracic radiation therapy.

8 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YLYi Liu
Yi Liu
SJSehyun Jung
Sehyun Jung
SHSoo-Yeon Hwang
Soo-Yeon Hwang
HJHyunji Jo
Hyunji Jo
YBYunjee Bang
Yunjee Bang
YKYoungjoo Kwon
Youngjoo Kwon
Background: Breast cancer remains a leading cause of cancer-related mortality in women, largely due to metastasis and treatment resistance. ELF3, an ETS transcription factor, has been linked to cancer progression; however, the mechanisms regulating its activity remain incompletely understood. Methods: ELF3 expression and its association with patient survival were analyzed using GEO datasets and the Kaplan–Meier Plotter platform. Functional studies were performed using ELF3 knockdown in breast cancer cell lines, followed by WST-1 assays and crystal violet staining. Protein–protein interactions were evaluated using co-expression analysis, immunofluorescence, split luciferase complementation, GST pull-down, and yeast two-hybrid assays. Cycloheximide chase assays were conducted to assess ELF3 protein stability. A panel of small molecules was screened to identify inhibitors of the ELF3-HSP27 interaction, and a lead compound was further validated using biochemical and functional assays. Antitumor activity was evaluated in a xenograft mouse model. Results: High ELF3 expression was associated with poorer overall survival in breast cancer patients. HSP27 was identified as a binding partner that stabilizes ELF3 protein, thereby promoting breast cancer cell proliferation. A novel small-molecule inhibitor disrupting the ELF3-HSP27 interaction suppressed cancer cell growth in vitro and reduced tumor growth in vivo. Conclusions: The ELF3-HSP27 interaction represents a previously unrecognized contributor to breast cancer progression, and its disruption provides a promising therapeutic strategy.